Objective: To determine patterns among gynecologic oncologists in sentinel lymph node mapping (SLNM) for endometrial cancer (EC) and cervical cancer (CC). Methods: A online survey assessing the practice of SLNM, including incidence, patterns of usage, and reasons for non-use was distributed to Society of Gynecologic Oncology candidate and full members in August 2017. Descriptive statistics and univariate analysis was performed. Results: The 1,117 members were surveyed and 198 responses (17.7%) were received. Of the 70% (n=139) performing SLNM, the majority reported use for both CC and EC (64.0%) or EC alone (33.1%). In those using SLNM in EC, the majority (86.6%) performed SLNM in >50% of cases for all patients (56.3%), International Federation of Gynecology and Obstetrics grade 1 (43.0%) and 2 (42.2%). Reported benefits of SLNM in EC were reduced surgical morbidity (89.6%), lymphedema (85.2%), and operative time (63.7%). Among those using SLNM for CC, the majority (73.1%) did so in >50% of cases. In EC, 77.2% and 21.3% reported that micro-metastatic disease (0.2-2.0 cm) and isolated tumor cells (ITCs) should be treated as node positive, respectively. In those not using SLNM for EC (n=64) and CC (n=105), concerns were regarding efficacy of SLNM and lack of training. When queried regarding training, 73.7% felt that SLNM would impact skill in full lymphadenectomy (LND).
INTRODUCTION
Endometrial cancer (EC) is the most common gynecologic malignancy diagnosed in the United States [1] . The standard of care for EC is hysterectomy and bilateral salpingooophorectomy via a minimally invasive surgical (MIS) approach [2] . Pelvic lymphadenectomy (LND) and/or para-aortic LND may be performed depending upon uterine factors, cancer stage and grade [3] . While 2 randomized control trials have studied the role of LND in EC and demonstrated no benefit in disease-specific or overall survival (OS), nodal information plays a crucial role in disease staging and treatment planning [4, 5] .
There is growing evidence supporting the role of sentinel lymph node mapping (SLNM) in EC [6] [7] [8] [9] [10] [11] [12] . In the prospective multicenter study by Rossi et al. [11] , specificity of greater than 97% was reported in patients with early stage EC undergoing SLNM. Similarly, data has increasingly demonstrated a role for SLNM in cervical cancer (CC) [13] [14] [15] [16] . SLNM has become standard protocol at some institutions but despite growing evidence supporting use of SLNM and support of organizations including National Comprehensive Cancer Network (NCCN) and the Society of Gynecologic Oncology (SGO) consensus group, this technology has not become widespread in the United States [12, [17] [18] [19] . Identification of the provider trends and attitudes and reasons for non-incorporation of SLNM may be helpful in guiding future studies and technologic advancements for MIS surgical staging in EC and CC.
The objective of this study is to identify trends in the utilization of SLNM for EC and CC among gynecologic oncologists and identify reasons for non-adoption of SLNM techniques among gynecologic oncologists.
MATERIALS AND METHODS

Study design
We designed an anonymous online questionnaire to assess member demographics, practice patterns, and attitudes regarding the use of SLNM in EC and CC. The study was approved by the Institutional Review Board at Cleveland Clinic Foundation, the Case Western Reserve University Comprehensive Cancer Center Protocol Review and Monitoring Committee (# 17-1050) and by the SGO for the purpose of surveying candidate members and full members.
Survey creation and study variables
The survey consisted of 24 questions querying demographics, SLNM usage in practice, perceived benefits of SLNM, reasons for non-uptake of SLNM, attitudes regarding usage patterns, and interest in additional training. The first part of the survey queried demographic variables including years of practice, gender, practice setting, and location. The second part of the survey assessed whether members were using SLNM for EC alone, CC alone, both EC and CC, or were not using SLNM in practice. If members reported use of SLNM in practice for EC, CC, or both, questions were asked regarding patterns of percentage of use, stage, and histologies in which SLNM was being used, surgical platform of use (MIS, multi-port laparoscopy, single port laparoscopy, robotic assisted laparoscopy; and laparotomy) and medium used for mapping (isosulfan blue, indocyanine green [ICG], technectium-99, and other). Questions were asked regarding use of full LND with alongside SLNM and personal mapping rate awareness and percentage, if known. For members who reported use of SLNM, questions were perceived benefits of SLNM in EC, CC, or both. In members not using SLNM for EC, CC, or both, they were asked for reasons for non-use (including concerns for efficacy of mapping, missing nodal positive disease and impact of ultra-staging, aid in training full LND, pathology department unsure how to process specimens, and lack of training during fellowship). Next, training practices for SLNM were assessed including where training was received, number of sentinel and full lymphadenectomies performed during fellowship and preparedness for SLNM after fellowship. Members were then queried whether they agreed, disagreed or were neutral regarding practice patterns in SLNM. Topics that were queried included perception of current data supporting SLNM in CC and EC, utility of current technology in SLNM, impact on fellowship training, whether they felt that micro-metastatic disease (0. 
Study participants
An E-mail invitation to participate in the anonymous study was distributed to all full and candidate gynecologic oncologist members of the SGO in August and September 2017. Fellows were excluded. Within the body of the E-mail, members were invited to participate in the confidential survey via the Research Electronic Data Capture (REDCap) website on a voluntary basis with an "opt-out" option [20] . No identifying data was collected, including the respondent's fellowship or current institution. Secure data storage was maintained with REDCap software (Vanderbilt, Nashville, TN, USA) [20] . The study was open for 4 weeks and members received an initial E-mail invitation, followed by up to 2 additional E-mails for members who did not complete the study which was automated in the REDCap program [20] . All members who were emailed the survey were included in the denominator of total surveys to calculate the response rate. 
Statistical analysis
RESULTS
Demographics
Of the 1,117 members who were surveyed, 198 responses (17.7%) were received. Table 1 displays the respondent demographics. Among those participating in the survey, there was a varied distribution of experiences within gynecologic oncology with over half (n=108; 54.5%) of respondents reporting more than 10 years of clinical practice. There was a broad geographic representation from across the United States among the responding gynecologic oncologists. The majority were in academic practice (n=103; 52.0%) or a combination of academic, and private practice (n=53; 26.8%). Among the 198 respondents, 70.2% (n=139) reported use of SLNM mapping for either EC, CC, or both in their practice.
Trends in SLNM for EC
Of the 139 of gynecologic oncologists using SLNM in their practice, 97.2% (n=135) endorsed use for EC. Table 2 displays the trends in usage in SLNM in EC. Robotic assisted laparoscopy was used as the most common surgical platform for SLNM in EC (n=109; 80.7%) and ICG was the most frequently used mapping dye (n=131; 97.0%).
The majority of respondents (n=94; 70.7%) utilized SLNM in over three-quarters of their surgical cases with 24.8% (n=33) using SLNM in all EC surgeries. When queried regarding usage of SLNM for EC, over half (56.3%; n=76) reported use for all patients regardless of histology without evidence of extra-uterine disease. Additionally, 43.0% (n=58) utilized SLNM for International Federation of Gynecology and Obstetrics (FIGO) 1 and 42.2% (n=57) for FIGO2. Use of SLNM was less frequently reported for patients with FIGO3 (n=30; 22.2%), complex atypical hyperplasia (n=26; 19.3%), high-risk histologies including serous carcinoma, clear cell carcinoma, and carcinosarcoma (n=24; 17.8%).
Over half of respondents (n=85; 63%) reported concurrent use of SLNM and full systematic LND in EC staging when they first adopted the technique. The median number of reported concurrent cases was 25 (range, 2-250). Less than half of respondents (n=59; 43.7%) were aware of their individual mapping rate for SLNM. Median unilateral SLNM rate was 90% (range, 0%-100%) and median bilateral SLNM rate was 85% (range, 50%-100%).
Among those performing SLNM for EC perceived benefits included reduced surgical morbidity (n=121; 89.6%), decreased lymphedema (n=115; 85.2%), lower blood loss (n=55; 40.7%), and increased speed vs. full LND (n=86; 63.7%). Additional reported benefits included faster recovery (n=28; 20.7%), improved detection of small volume metastatic disease (n=8; 5.9%), and reduced lymphocyst or lymphocele formation (n=3; 2.2%).
Trends in SLNM for cervical cancer
Of the 139 of gynecologic oncologists using SLNM in their practice, 67.0% (n=93) reported use for CC. Table 3 displays the trends in usage in SLNM in CC. Similar to EC, robotic assisted laparoscopy was used as the most common surgical platform for SLNM in CC (n=74; 80.0%) and ICG was the most frequently used mapping dye (n=86; 92.5%). The majority of respondents (n=57; 64.0%) utilized SLNM in over three-quarters of their surgical cases for CC. When queried regarding usage of SLNM for CC, the majority used the technology for stage IA2 (n=87; 93.5%) and stage IB1 (n=88; 95.0%) disease. Additionally, 50.5% (n=47) utilized SLNM for stage IA1 and 40.9% (n=38) for stage IB2 patients. Over three-quarters of respondents (n=72; 77.4%) reported concurrent use of SLNM and full systematic LND in CC staging when they first adopted the technique with a median number of 20 cases (range, 5-400). Less than one-third of respondents (n=25; 26.9%) were aware of their individual mapping rate for SLNM in CC, specifically. The median reported SLNM rate was 91.5% (range, 70%-100%). Trends in sentinel lymph node mapping Among gynecologic oncologists utilizing SLNM for CC perceived benefits included reduced surgical morbidity (n=82; 88.2%), decreased lymphedema (n=81; 87.1%), lower blood loss (n=38; 40.9%), and increased speed vs. full LND (n=59; 63.4%). Additional reported benefits included faster recovery (n=18; 19.4%) and improved detection of small volume metastatic disease (n=9; 9.7%).
Reasons for non-uptake of SLNM
Of the 198 gynecologic oncologists who responded to the survey, 30% (n=59) did not use SLNM in their practice in the management of both EC and CC. When non-use was stratified by type of malignancy, 31.8% (n=63) reported non-use of SLNM for EC and 53.0% (n=105) reported non-use of SLNM for CC. Table 4 displays reported reasons for non-use of SLNM in EC and CC.
Reported reasons for non-use of SLNM for EC staging included uncertainty of data (n=26; 46.0%), lack of training (n=23; 36.5%), technology (n=22; 34.9%), issues with specimen processing for ultra-staging (n=11; 17.5%), and to aid with training of fellows in full LND (n=8; 12.7%). Concerns reported by non-users regarding SLNM included efficacy of mapping (n=20; 31.7%), implications of missing nodal positive disease (n=18; 28.6%), and uncertainty for how SLNM data will impact patient outcomes (n=20; 31.7%). Similarly for SLNM in CC, respondents reported uncertainty of data (n=62; 59.0%), lack of training (n=22; 21.0%), technology (n=19; 18.1%), and issues with specimen processing for ultrastaging (n=10; 9.5%) as reasons for non-uptake. Concerns reported by non-users regarding SLNM included efficacy of mapping (n=25; 23.8%), implications of missing nodal positive disease (n=34; 32.4%) and uncertainty for how SLNM data will impact patient outcomes (n=20; 19.0%). 
Provider attitudes toward SLNM
Provider Attitudes and Practices toward SLNM are displayed in Table 5 . For EC, 45.5% (n=90) of respondents reported that data supported the use of SLNM in all EC cases regardless of histology, while 75.8% (n=150) felt that SLNM was supported in low-risk histologies (FIGO1/2) only. While the majority of respondents (n=154; 77.2%) agreed that micrometastatic disease (0.2-2.0 cm) should be treated as node positive, only 21.3% (n=42) agreed for ITCs. When queried regarding practice patterns after positive lymph nodes were identified after SLNM, the majority reported proceeding direct to adjuvant treatment (n=108; 54.5%) or performing additional imaging to evaluate for additional metastatic disease (n=70; 35.4%).
When queried regarding SLNM in CC, approximately one-third of respondents both independently agreed (n=68; 34.4%) and disagreed (n=55; 27.8%) that data supported use.
Similar to EC, the majority of respondents (n=141; 71.2%) agreed that micro-metastatic disease (0.2-2.0 cm) should be treated as node positive, only 34.3% (n=68) Trends in sentinel lymph node mapping their likelihood of uptake of the practice (n=137; 69.1%), the majority agreed that SLNM would impact fellows training and skill level in performing full LND for EC (n=146; 73.7%). Table 6 displays results of univariate analysis for provider factors associated with usage of SLNM in EC and CC. There were no significant differences in the utilization of SLNM based upon gender (p=0.29), duration of practice as a gynecologic oncologist (p=0. setting (p=0.99), or location of practice (p=0.59). Among providers not using SLNM, the vast majority had not been trained to do so (n=47; 79.7%) compared to those performing SLNM routinely (n=20; 14.8%) (p<0.001).
Provider factors associated with usage of SLNM
Current training practices in SLNM
Of the 127 respondents (64.1%) who had been trained in SLNM, the majority (n=85; 66.9%) were trained to perform the procedure as attending physicians. Among those not using SLNM in their practice, 76.7% reported that they would be interested in further training through surgical videos, case proctoring and observation. Among those trained in fellowship, 83.3% (n=35) felt prepared to independently perform SLNM at the end of fellowship.
DISCUSSION
The SLNM is a targeted approach to MIS staging for EC and CC. This study was designed to identify usage patterns in SLNM and determine reasons for non-adoption. While SLNM for EC and CC is being utilized at many institutions and has received endorsement by NCCN and SGO, SLNM accounted for only 10% of lymphadenectomies for EC in 2015 [12, [17] [18] [19] . Our results demonstrate that SLNM is more prevalent than previously reported with over two-thirds of responding gynecologic oncologists performing SLNM. Among the one-third Trends in sentinel lymph node mapping reporting non-use of SLNM, the most common reasons were uncertainty of the data, concern for missing positive nodes, and efficacy of mapping. These reservations are interesting given that several studies have identified high accuracy and net present value (NPV) of SLNM and increased detection of nodal metastasis with ultra-staging [8] [9] [10] [11] [14] [15] [16] [17] 21] .
A dichotomy identified in this study is provider attitudes towards utilization of SLNM in low vs. high-risk EC. Patients with high-risk EC may have the most to gain from SLNM due to their increased risk for lymph node metastasis leading to adjuvant treatment which can increase morbidity. Emerging data supports SLNM in high-risk EC [10, [22] [23] [24] . In a prospective study of patients with high grade EC, SLNM alone detected 95% of positive lymph nodes with a NPV of 1.4% [10] . At present, SGO supports the NCCN SLN algorithm for low grade (FIGO1/2) EC and comments that SLNM is feasible in high-risk patients with consideration for concurrent full LND until more data is available [18] . Further studies are needed focusing on disease free and OS for patients with high-risk EC undergoing SLNM.
Inherent to SLNM is the pathological ultra-staging of sentinel nodes leading to the detection of micrometastasis (MM) and ITCs, but the significance of low-volume metastases in CC and EC is unclear. In this study, the majority of respondents agreed that MM should be treated as node positive, but less than one-third felt that ITCs should be treated as node positive. Similarly, in a study by St Clair et al. [25] , the recurrence-free survival at 36 months was comparable for ITCs and MM (86%) but significantly decreased in patients with macrometastasis (71%). Additional research is needed to understand the prognostic impact of ITCs and MM after SLNM and whether low-volume metastasis should guide adjuvant treatment.
Training in LND is required for gynecologic oncology fellows [26] . Our study validated concerns that SLNM may impact training, with over 70% reporting this concern. Fellows should be trained to perform the necessary surgical techniques, which may include both full LND and SLNM via MIS. Interestingly, among gynecologic oncologists not using SLNM, the majority expressed interested in additional training. Providing both trainees and attending gynecologic oncologists with opportunities for training in SLNM and full LND should be prioritized.
An individual surgeon's learning curve and awareness of mapping rates is critical to high accuracy and low false negative rates in SLNM. Studies in SLNM for vulvar cancer have demonstrated the importance of experience, high-volume and surgeon self-awareness to ensure acceptable NPVs [27, 28] . In our study, less than 50% of those performing SLNM for EC and CC reported an awareness of their mapping rates and the majority of providers performing SLNM were not or had not performed concurrent validation with full LND. While the literature reports a low false negative rate for SLNM, it is important to note that these studies are often conducted by high-volume surgeons and may not be generalizable to all. The SGO recommends that completion LND be performed, in addition to SLNM, until the individual surgeon's experience is comparable with currently published literature [18] . Surgeon awareness of mapping rates and performing concurrent SLNM with full LND is important to ensure acceptable false negative rates.
The survey response rate of 17.7% is a major limitation of the study and in the interpretation of findings. The decision to survey the entire SGO cohort, including both full and candidate members, was deliberate to reflect contemporary practice patterns and attitudes for SLNM while acknowledging that engagement of a large multi-disciplinary group may be lower.
